Close menu

June 12th, 2023 | 08:00 CEST

Disruption! From now on, everything will be different: PayPal, BYD, BioNXt

  • Biotechnology
  • Pharma
  • Electromobility
  • Software
Photo credits:

What is now called disruption in the startup scene has always existed. It refers to creative destruction, cutting old ties and rethinking things from the ground up. Companies that create marketable products in this way have an edge over the competition - and score points on the market with their uniqueness. We present three titles.

time to read: 3 minutes | Author: Nico Popp
ISIN: PAYPAL HDGS INC.DL-_0001 | US70450Y1038 , BYD CO. LTD H YC 1 | CNE100000296 , Bionxt Solutions Inc. | CA0909741062

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    PayPal's recipe for success: Easier, faster, cheaper

    When the payment service PayPal was founded in Palo Alto, California, in 1998, most people in Germany still dialled into the Internet via modem or ISDN. Marketplaces, such as online auction houses, only spread gradually and lived above all from their innovative power. Peter Thiel's team quickly realized that the comparatively young Internet would soon be of great commercial importance and that a payment service was needed. The following years can be summarized quickly: Since 2004, PayPal has been available in Germany, and since 2007, the Company has also had a banking licence in Europe.

    Compared to traditional financial institutions, PayPal quickly gained the upper hand on the internet - even though credit cards were initially the number one means of payment online. However, problems with security and handling drove customers to PayPal in droves. The cooperation with eBay, to which PayPal even belonged for a time, also contributed to the spread of the service. Those who regularly bought things at auction soon no longer wanted to use bank transfers and appreciated buyer protection. Today, PayPal is so strongly positioned in the market that one can trust the share despite recession worries. Despite the share price losses, PayPal is still up more than 65% over eight years.

    BYD: Flat screen instead of sports chassis

    The Chinese carmaker BYD is also something of a revolutionary. In the same period, the share even generated a return of a whopping 429% - and that despite the fact that the share is also already trading well below its all-time high. Why is that? BYD was an early adopter of electric mobility. This spring, it even stopped building internal combustion vehicles altogether. Another unique selling point of BYD is that the Company relies heavily on connectivity and technical bells and whistles. Large displays, WLAN, Bluetooth and lots of LEDs are more convincing to Chinese customers than a tight chassis. Why this is so is not surprising - after all, cars on China's roads send data to the authorities every thirty seconds. Driving pleasure is then quickly redefined. But back to BYD: As a promising company in the most important car market, the share is naturally highly rated. Whether the exit of Berkshire Hathaway or worries about a trade war between East and West: this market position is convincing and unique.

    BioNxt does it better and cheaper

    Completely free of worries about trade wars or financial crises are shareholders of the Canadian biotech BioNxt. The Company has positioned itself in various promising areas and sees itself as a problem solver within the healthcare system. The German subsidiary Vektor Pharma TF GmbH has developed a patch around the well-known Parkinson's drug rotigotine that can compete with original preparations in studies. A clinical trial of the product is currently underway, with the results expected by late summer. Only a few months ago, a court in the US cleared the way for generics in this very field. Also, a few months ago, BioNxt received an order to produce an orally soluble product. To fulfil this order, the Company has invested in a coating and cutting machine at its Biberach site.

    The business field of innovative dosage forms, which is also gaining commercial momentum, is extremely promising for BioNxt Solutions. The Company does not rule out acting as a contract manufacturer in other areas in the future. The dose can be adjusted depending on how effectively an active substance reaches the patient. This saves costs and strikes a chord with already cash-strapped healthcare systems worldwide. The incipient commercialization can be an opportunity for investors. In parallel, BioNxt is involved in the diagnostics sector, offering self-tests related to oral health. There is already a letter of intent for the production of biosensor products for testing inflammatory diseases of the oral cavity, such as those that occur as a side effect of drugs for opioid abuse, for the US market.

    Companies that have rethought tried-and-tested products from the ground up are also successful on the stock market - good examples are PayPal and BYD. BioNxt Solutions has made significant progress in the commercialization of its product range in recent months. If the positive trend continues and the figures are right, the share, which currently represents an enterprise value of around CAD 58 million, should be seen by many investors with new eyes.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Juliane Zielonka on April 18th, 2024 | 07:00 CEST

    Volkswagen, Altech Advanced Materials, BYD - who can benefit from China's rise

    • Innovations
    • Technology
    • Electromobility
    • Batteries

    Chinese companies such as BYD benefit from state subsidies and domestic access to raw materials. BYD's subsidies have risen from EUR 220 million in just three years to EUR 2.1 billion. These sums are helping BYD dominate the Chinese electric vehicle market and increasingly penetrate the European market. Volkswagen cannot escape the pull of China either. As part of its "In China, for China" strategy, Volkswagen is expanding its cooperation network with Chinese partners. The aim is to reduce costs significantly in the development of EV technology. For companies like Altech Advanced Materials, close cooperation with Chinese market leaders such as BYD and Volkswagen offers the opportunity to commercialize innovative battery technologies that meet the needs of the changing market. One of these innovations, made in Germany by Altech Advanced Materials, increases the longevity of EV batteries by 30%. Here are the details.


    Commented by Stefan Feulner on April 16th, 2024 | 07:40 CEST

    Formycon, Defence Therapeutics, Morphosys - Significant movement in the biotech sector

    • Biotechnology
    • Pharma
    • Cancer

    At the moment, investors are focusing on gold and Bitcoin in addition to the most important indices, like the DAX and Dow Jones. Meanwhile, the biotechnology sector is barely mentioned in the local newspapers. However, the market is on the move, and the wave of takeovers continues unabated. Recently, the Danish pharmaceutical company Genmab announced it was acquiring the private biotech company ProfoundBio for USD 1.8 billion in cash. The acquisition is intended to help deepen the cancer pipeline with next-generation antibody-drug conjugate therapies. Big Pharma is likely to make further acquisitions in this area in the near future.


    Commented by Armin Schulz on April 15th, 2024 | 06:15 CEST

    Varta, Carbon Done Right Developments, Bayer - Buy when the cannons are firing?

    • Sustainability
    • renewableenergies
    • Pharma

    The stock market is a fascinating place where investors have to weigh up their opportunities and risks. An often-quoted stock market adage is: "Buy when the cannons are firing". The idea behind this is that one can find opportunities for lucrative investments in times of crisis when market sentiment is particularly poor. Warren Buffett also supports the idea of buying securities or companies at times when the majority of investors are pessimistic, causing prices to fall below the actual value of the investments. He said: "Be greedy when others are fearful and be fearful when others are greedy." We have selected three candidates who have recently lost ground and shed light on whether an investment is worthwhile.